Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mesoblast Limited ( (AU:MSB) ) has shared an announcement.
Mesoblast Limited has notified the market of the issue of 3,245,600 unquoted options under its employee incentive scheme, with various exercise prices and expiry dates, effective March 16, 2026. The move expands the company’s pool of equity-based incentives aimed at staff retention and alignment, modestly increasing potential future dilution while reinforcing its strategy of using options to incentivise employees in a competitive biotech talent market.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is an Australia-based biotechnology company listed on the ASX under the code MSB. The company focuses on developing cell-based and regenerative therapies, positioning itself within the biopharmaceutical sector targeting advanced medical treatments.
Average Trading Volume: 3,990,037
Technical Sentiment Signal: Hold
Current Market Cap: A$2.67B
For detailed information about MSB stock, go to TipRanks’ Stock Analysis page.